Hinova Pharmaceuticals (SH:688302) Zheng Quan Shi Bao Wang·2025-07-04 14:59Core Viewpoint - The successful launch of the self-developed Class 1 anti-cancer drug, Deuteroenzalutamide, by Haichuang Pharmaceutical marks a significant milestone for the company and its mission to create effective medicines for the benefit of society [1][2]. Company Overview - Haichuang Pharmaceutical is a global innovative drug company focused on cancer and metabolic diseases, with four core technology platforms: PROTAC targeted protein degradation, deuterated drug development, targeted drug discovery and validation, and translational medicine [2]. - The company has been recognized in two national "Major New Drug Creation" science and technology projects and several provincial and municipal research projects, with eight products in development and one product already launched [2]. Product Details - Deuteroenzalutamide soft capsules are designed for adult patients with metastatic castration-resistant prostate cancer who have experienced disease progression after treatment with abiraterone acetate and chemotherapy, and who have not previously received new androgen receptor inhibitors [1]. - Prostate cancer is the second most common cancer among men globally, with 1.467 million new cases reported in 2022, and the incidence in China has been rising, with 134,000 new cases in the same year [1]. Market Launch - The product received approval from the National Medical Products Administration at the end of May and began national distribution in late June, with the first prescription issued shortly after [2]. - Patients can purchase the product at major provincial capital DTP pharmacies with a doctor's prescription, indicating its significant clinical value and urgent demand [2].